UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 22, 2022

Date of Report (date of earliest event reported)



Cutera, Inc.

(Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 000-50644 (Commission File Number) 77-0492262 (I.R.S. Employer Identification Number)

3240 Bayshore Blvd.
Brisbane, California 94005
(Address of principal executive offices)

(415) **657-5500**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock (\$0.001 par value)	CUTR	The NASDAQ Stock Market, LLC

N/A

(Former name or former address, if changed since last report)Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company $\ \square$
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 2.02. Results of Operations and Financial Condition.

On February 22, 2022, Cutera, Inc. ("Cutera" or the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2021. Cutera hereby incorporates by reference herein the information set forth in its press release dated February 22, 2022, a copy of which is attached hereto as Exhibit 99.1. Except as otherwise provided in the press release, the press release speaks only as of the date of such press release and it shall not create any implication that the affairs of Cutera have continued unchanged since such date.

The Company will host a conference call for interested parties commencing Tuesday, February 22, 2022 at 1:30 p.m. PDT (4:30 p.m. EDT), during which the Company will discuss the financial results. To participate in the conference call, dial 1-877-705-6003 (domestic) or +1-201-493-6725 (international) and refer to the Conference Code: 13726648. The conference call will be also available to interested parties through a live audio webcast and accessible through the Investor Relations section of the Cutera corporate website at www.cutera.com.

The information provided pursuant to this Item 2.02 is to be considered "furnished" pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any of Cutera's reports or filings with the Securities and Exchange Commission, whether made before or after the date hereof, except as expressly set forth by specific reference in such report or filing.

Except for the historical information contained in this report, the statements made by Cutera are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Cutera's future financial performance could differ significantly from the expectations of management and from results expressed or implied in the press release. Please refer to the last paragraph of the text portion of the press release for further discussion about forward-looking statements. For further information on risk factors, please refer to "Risk Factors" contained in Cutera's most recently filed Form 10-K and its subsequent filings with the Securities and Exchange Commission, as well as in the press release attached as Exhibit 99.1 hereto. Cutera disclaims any obligation or duty to update or modify these forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release of Cutera, Inc. dated as of February 22, 2022.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUTERA, INC.

Date: February 22, 2022 /s/ ROHAN SETH

Rohan Seth

Chief Financial Officer



Cutera, Inc. Announces Fourth Quarter and Full-Year 2021 Financial Results along with 2022 Outlook

Achieved Record Revenue in Fourth Quarter and Full-Year 2021

BRISBANE, California, February 22, 2022 — Cutera, Inc. (NASDAQ: <u>CUTR</u>) ("Cutera" or the "Company"), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today reported financial results for the fourth quarter and full-year ended December 31, 2021.

Fourth Quarter 2021 Financial and Operational Highlights

- Revenue was \$65.6 million, an increase of 31% from the prior-year period, driven by strong performance across the business, with particular strength in North American Capital Equipment;
 - Capital Equipment revenue of \$43.6 million increased 44% over the prior-year period;
 - Recurring revenue, defined as the combination of Skincare, Consumable Products, and Service, was \$22.1 million, an increase of 12% over the prior-year period;
 - Skincare revenue of \$10.7 million increased 2% over the prior-year period, impacted by 3Q21 pre-buying in advance of the
 planned price increase;
 - Consumable Product revenue of \$5.4 million grew 77% over prior-year period; and
 - Service revenue of \$6.0 million decreased 4% over the prior-year period;
- Gross Margin was 58.2%, compared to 56.2% in the prior-year period, driven by better sales mix and continued leverage, partially offset by
 modest inflationary pressures;
- Operating Expenses were \$40.2 million in the quarter, as compared to \$26.6 million in the prior-year period, driven by variable costs from increased sales and by investments in our Acne program;
- Net loss was \$3.9 million, or (\$0.22) per fully diluted share, compared to a net income of \$2.2 million, or \$0.12 per fully diluted share, in the prior-year period; and
- Adjusted EBITDA was \$4.3 million in the period as compared to \$4.7 million in the prior-year period. Excluding Acne program spend of \$4.6 million in the quarter, our adjusted EBITDA would have been \$8.9 million.

Full-Year 2021 Financial and Operational Highlights

- Revenue was \$231.3 million, an increase of 57% from the prior-year period;
 - Capital Equipment revenue of \$139.6 million increased 54% over the prior-year period;
 - Recurring revenue, defined as the combination of Skincare, Consumable Products, and Service, was \$91.6 million, an increase of 61% over the prior-year period;
 - Skincare revenue of \$49.7 million increased 98% over the prior-year period;
 - Consumable Product revenue of \$16.4 million increased 77% over the prior-year period; and
 - Service revenue of \$25.6 million increased 13% over the prior-year period;
- Gross Margin was 57.6%, compared to 51.3% in the prior-year period;
- Operating Expenses were \$131.3 million, as compared to \$98.6 million in the prior-year period;
- Net Income was \$2.1 million, or \$0.11 per fully diluted share, compared to a net loss of \$23.9 million, or (\$1.43) per fully diluted share, a year ago; and
- Adjusted EBITDA was \$20.7 million as compared to a loss of \$4.8 million a year ago. Excluding full-year Acne program spend of \$9.5 million, our adjusted EBITDA would have been \$30.2 million, a seven-fold improvement.

"I am pleased with our strong fourth-quarter performance, which was driven by our team's outstanding commercial execution and supported by robust underlying patient demand. I am particularly encouraged that our North American Capital business eclipsed Pre-Covid levels and delivered 56% growth in the quarter" commented Dave Mowry, Chief Executive Officer of Cutera, Inc. "We anticipate that this top-line momentum will continue as we move through the year, driven by our growing capital equipment pipeline and the strong ongoing patient demand. In light of our business strength, in combination with future product launches, we are tremendously excited for the year ahead."

2022 Outlook

The Company expects full-year 2022 constant currency revenue in the range of \$255 million to \$260 million, based on our current product portfolio. For the sake of clarity, this guidance does not include any revenue from our Acne device program.

Conference Call

The Company's management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating on the call will be Dave Mowry, Chief Executive Officer and Rohan Seth, Chief Financial Officer.

To participate in the conference call, dial 1-877-705-6003 (domestic) or + 1-201-493-6725 (international) and refer to the Conference Code: 13726648.

The call will also be webcast and can be accessed from the Investor Relations section of Cutera's website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has developed innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.

*Use of Non-GAAP Financial Measures

In this press release, in order to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations and net income (loss) per diluted share. Non-GAAP adjustments include stock-based compensation, depreciation, amortization, executive and other non-recurring separation costs, customer relationship management ("CRM") and enterprise resource planning ("ERP") system costs, non-recurring legal and litigation costs, as well as the net tax impact of excluding these items. From time to time in the future, there may be other items that we may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. The Company has not provided a reconciliation of non-GAAP guidance measures to the corresponding GAAP measures on a forward-looking basis due to the potential significant variability, limited visibility, unpredictability, or unique non-recurring nature of the items. Forward-looking non-GAAP measures include adjusted EBITDA. The Company defines adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, stock-based compensation, executive and other non-recurring separation costs, customer relationship management and enterprise resource planning system costs, and non-recurring legal and litigation costs.

Company management uses these measurements as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per diluted share exclude the following:

Non-cash expenses for stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expense related to grants of options, employee stock purchase plan, and performance and restricted stock. Depending upon the size, timing and the terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;

Depreciation and amortization. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;

Executive and other non-recurring separation costs. We have excluded costs associated with the resignation of our former Executive Officers in calculating our non-GAAP operating expenses and net income measures. We exclude these and other non-recurring employee separation costs because we believe that these items do not reflect future operating expenses;

Customer Relationship Management. We have excluded CRM system costs related to direct and incremental costs incurred in connection with our multi-phase implementation of a new CRM solution and the related technology infrastructure costs. We exclude these costs because we believe that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance;

Enterprise Resource Planning. We have excluded ERP system costs related to direct and incremental costs incurred in connection with our multi-phase implementation of a new ERP solution and the related technology infrastructure costs. We exclude these costs because we believe that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance; and

Non-recurring legal and litigation costs. We have excluded costs incurred related to third party litigation and disputes, that are of a non-recurring nature.

The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations.

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements include, but are not limited to, Cutera's plans, objectives, strategies, financial performance and outlook, product launches and performance, trends, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, the Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "seek," "guidance," "predict," "potential," "likely," "believe," "will," "should," "expect," "anticipate," "estimate," "plan," "intend," "forecast," "foresee" or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond the Company's control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the "Risk Factors" section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-,8 and other documents filed from time to time with the United States Securities and Exchange Commission by Cuter

All information in this press release is as of the date of its release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Cutera's financial performance for the fourth quarter and full year ended December 31, 2021, as discussed in this release, is preliminary and unaudited, and subject to adjustment.

Cutera, Inc. Anne Werdan Director, Corporate Communications 415-657-5500 awerdan@cutera.com

CUTERA, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited)

	D	ecember 31, 2021	Γ	December 31, 2020
Assets				
Current assets:				
Cash and cash equivalents	\$	164,164	\$	47,047
Accounts receivable, net		31,449		21,962
Inventories		39,503		28,508
Other current assets and prepaid expenses		14,545		8,779
Total current assets		249,661		106,296
Property and equipment, net		3,019		2,299
Deferred tax asset		778		643
Operating lease right-of-use assets		14,627		17,076
Goodwill		1,339		1,339
Other long-term assets		10,169		5,080
Restricted cash		700		_
Total assets	\$	280,293	\$	132,733
T 1994 10, 11 11 17 4				
Liabilities and Stockholders' Equity				
Current liabilities:	ф	7 001	φ	C CO 4
Accounts payable	\$	7,891	\$	6,684
Accrued liabilities		54,100		32,295
Operating leases liabilities PPP loan payable		2,419		2,260
Deferred revenue		0.400		3,630
		9,490		9,489
Total current liabilities		73,900		54,358
Deferred revenue, net of current portion		1,335		1,748
Operating lease liabilities, net of current portion		13,483		15,950
PPP loan payable, net of current portion				3,555
Convertible notes, net of unamortized debt issuance costs		134,243		_
Other long-term liabilities		763		242
Total liabilities		223,724		75,853
Stockholders' equity:				
Common stock		18		18
Additional paid-in capital		114,724		117,097
Accumulated deficit		(58,173)		(60,235)
Total stockholders' equity		56,569		56,880
Total liabilities and stockholders' equity	\$	280,293	\$	132,733

CUTERA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data) (unaudited)

		Three Mo	nths	s Ended	Twelve Mo	nths	Ended
]	December 31, 2021		December 31, 2020	December 31, 2021		December 31, 2020
Products	\$	59,647	\$	43,723	\$ 205,703	\$	125,113
Service		5,982		6,220	25,567		22,570
Total net revenue		65,629		49,943	231,270		147,683
Products		23,565		17,999	83,048		58,325
Service		3,883		3,878	15,117		13,586
Total cost of revenue		27,448		21,877	98,165		71,911
Gross profit		38,181		28,066	133,105		75,772
Gross margin %		58.2 %		56.2 %	57.6 %		51.3 %
Operating expenses:							
Sales and marketing		24,094		14,656	76,762		52,766
Research and development		6,804		4,029	21,568		14,322
General and administrative		9,312		7,938	32,945		31,512
Total operating expenses		40,210		26,623	131,275		98,600
Income (loss) from operations	· · ·	(2,029)		1,443	 1,830		(22,828)
Interest and other income (expense), net							
Amortization of debt issuance costs		(218)		_	(710)		_
Interest on convertible notes		(777)		_	(2,514)		_
Gain on extinguishment of PPP loan		_		_	7,185		_
Other income (expense), net		(430)		7	 (2,406)		(579)
Income (loss) before income taxes		(3,454)		1,450	3,385		(23,407)
Income tax expense (benefit)		481		(738)	1,323		470
Net income (loss)	\$	(3,935)	\$	2,188	\$ 2,062	\$	(23,877)
Net income (loss) per share:							
Basic	\$	(0.22)	\$	0.12	\$ 0.12	\$	(1.43)
Diluted	\$	(0.22)	\$	0.12	\$ 0.11	\$	(1.43)
Weighted-average number of shares used in per share calculations:							
Basic		17,980		17,653	 17,891		16,691
Diluted		17,980		17,840	18,362		16,691

CUTERA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)

	Three Mo	nths Ended	Twelve Mo	nths Ended
	December 31, 2021	December 31, 2020	December 31, 2021	December 31, 2020
Cash flows from operating activities:			•	·
Net income (loss)	\$ (3,935)	\$ 2,188	\$ 2,062	\$ (23,877)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:				
Stock-based compensation	4,665	2,052	13,172	10,109
Depreciation and amortization	330	338	1,344	1,394
Amortization of contract acquisition costs	427	579	1,857	2,593
Amortization of debt issuance costs	218	_	710	_
Impairment of capitalized cloud computing costs	_	_	182	805
Change in deferred tax asset	(189)	(143)	(135)	(220)
Provision for credit losses	(14)	394	87	2,144
Gain on extinguishment of PPP loan	_	_	(7,185)	_
Change in right-of-use asset	611	705	2,292	2,522
Other	46	183	1	513
Changes in assets and liabilities:				
Accounts receivable	(675)	(4,759)	(9,574)	(2,550)
Inventories	(4,010)	825	(10,936)	5,413
Other current assets and prepaid expenses	(1,195)	(1,891)	(5,766)	(3,164)
Other long-term assets	(3,641)	(366)	(7,128)	(2,067)
Accounts payable	632	(148)	1,207	(6,034)
Accrued liabilities	9,826	5,169	21,608	161
Operating lease liabilities	(578)	_	(2,151)	(1,598)
Deferred revenue	145	(587)	(412)	(2,985)
Income tax liability	_	(93)	<u> </u>	(93)
Net cash provided by (used in) operating	2,663	4,446	1,235	(16,934)
Cash flows from investing activities:				
Acquisition of property, equipment and software	(633)	(505)	(1,015)	(1,279)
Disposal of property and equipment	_	30	71	30
Proceeds from sales of marketable investments	_	5,648	_	5,648
Proceeds from maturities of marketable investments	_	9,050	_	28,050
Purchase of marketable investments	_	(1,649)	_	(26,060)
Net cash provided by (used in) investing activities	(633)	12,574	(944)	6,389
Cash flows from financing activities:				
Proceeds from exercise of stock options and employee stock purchase plan	709	723	2,765	1,579
Proceeds from PPP loan	_	_	_	7,167
Gross proceeds from equity offering	_	_	_	28,798
Issuance costs on the public offering	_	_	_	(2,303)
Purchase of capped call	_	_	(16,134)	_
Proceeds from issuance of convertible notes	_	_	138,250	_
Payment of issuance costs of convertible notes	_	_	(4,717)	_
Taxes paid related to net share settlement of equity awards	(213)	(88)	(2,176)	(3,428)
Payments on finance lease obligations	(148)	(2)	(462)	(537)
Net cash provided by financing activities	348	633	117,526	31,276
Net increase in cash, cash equivalents and restricted cash	2,378	17,653	117,817	20,731
Cash, cash equivalents, and restricted cash at beginning of period	162,486	29,394	47,047	26,316
Cash, cash equivalents, and restricted cash at end of period	\$ 164,864	\$ 47,047	\$ 164,864	\$ 47,047

CUTERA, INC. CONSOLIDATED FINANCIAL HIGHLIGHTS (in thousands, except percentage data) (unaudited)

	Three Months Ended				% Change		Twelve Mo	nths !	Ended	% Change		
	Decei	mber 31, 2021	Dece	ember 31, 2021	2021 Vs 2020	De	ecember 31, 2021	Dec	ember 31, 2021	2021 Vs 2020		
Revenue By Geography:												
North America	\$	35,827	\$	23,966	+49.5 %	\$	111,621	\$	69,455	+60.7 %		
Japan		16,924		16,089	+5.2 %		70,235		43,265	+62.3 %		
Rest of World		12,878		9,888	+30.2 %		49,414		34,963	+41.3 %		
Total Net Revenue	\$	65,629	\$	49,943	+31.4 %	\$	231,270	\$	147,683	+56.6 %		
Rest of World (including Japan) as a percentage of total revenue		45.4 %		52.0 %			51.7 %		53.0 %			
Revenue By Product Category:												
Systems												
 North America 	\$	28,747	\$	18,426	+56.0 %	\$	86,100	\$	50,721	+69.8 %		
 Rest of World (including Japan) 		14,807		11,719	+26.4 %		53,533		40,045	+33.7 %		
Total Systems		43,554		30,145	+44.5 %		139,633		90,766	+53.8 %		
Consumables		5,361		3,023	+77.3 %		16,401		9,286	+76.6 %		
Skincare		10,732		10,555	+1.7 %		49,669		25,061	+98.2 %		
Total Products		59,647		43,723	+36.4 %		205,703		125,113	+64.4 %		
Service		5,982		6,220	(3.8)%		25,567		22,570	+13.3 %		
Total Net Revenue	\$	65,629	\$	49,943	+31.4 %	\$	231,270	\$	147,683	+56.6 %		

		Three Mo	nths E	nded		Twelve Mo	nths	Ended
	December 31, 2021		De	December 31, 2020		December 31, 2021	Ι	December 31, 2020
Pre-tax Stock-Based Compensation Expense:	·							
Cost of revenue	\$	500	\$	306	\$	1,408	\$	1,665
Sales and marketing		1,206		767		3,160		3,384
Research and development		1,156		325		2,784		1,670
General and administrative		1,803		654		5,820		3,390
	\$	4,665	\$	2,052	\$	13,172	\$	10,109

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data) (unaudited)

Three Months Ended December 31, 2021

					Timee	months Ended Deceme	Jer 51, 2021				
		GAAP		Depreciation and Amortization	Stock-Based Compensation	CRM and ERP Implementation Cost	Severance (RIF)	Legal - Lutronic	Other Adjustments		ion-GAAP
Net revenue	\$	65,629		_	_	_	_	_	_	\$	65,629
Cost of revenue		27,448		(94)	(500)	_	_	_	_		26,854
Gross profit	_	38,181	_	94	500						38,775
Gross margin %		58.2 9	%								59.1 %
Operating expenses:											
Sales and marketing		24,094		(593)	(1,206)	_	_	_	_		22,295
Research and development		6,804		(49)	(1,156)	_	_	_	_		5,599
General and administrative		9,312		(4)	(1,803)	(711)	_	(222)	_		6,572
Total operating expenses		40,210	40210	(646)	(4,165)	(711)		(222)	_		34,466
Income (loss) from operations		(2,029)		740	4,665	711		222			4,309
Interest and other income (expense), net											
Amortization of debt issuance costs		(218)		_	_	_	_	_	_		(218)
Interest on convertible notes		(777)		_	_	_	_	_	_		(777)
Other expense		(430)		_	_	_	_	_	_		(430)
Total interest and other income (expense), net		(1,425)		_					_		(1,425)
Income (loss) before income taxes		(3,454)		740	4,665	711	_	222			2,884
Income tax expense		481		_	_	_	_	_	_		481
Net income (loss)	\$	(3,935)	_	\$ 740	\$ 4,665	\$ 711	\$ —	\$ 222	\$ —	\$	2,403
Net income (loss) per share:											
Basic	\$	(0.22)	_							\$	0.13
Weighted-average number of shares used in per share calculations:											
Basic		17,980									17,980
Operating expenses as a % of net revenue		GAAP	_								Non-GAAF
Sales and marketing	_	36.7 9	<u>/</u>								34.0 %
Research and development		10.4 9									8.5 %
General and administrative		14.2 9									10.0 %
Seneral and administrative		61.3 9	_								52.5 %
	_	01.5	0							_	32.3 %

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data) (unaudited)

							Three	Months Ended D)ecen	nber 31, 2020					
		GAAP	•	oreciation and ortization		Stock-Based Compensation		RM and ERP plementation/ write-off	:	Severance (RIF)		l - Former CFO ent/Lutronic	ther stments	No	n-GAAP
Net revenue	\$	49,943		_		_		_		_		_	_	\$	49,943
Cost of revenue	*	21,877		(174)		(306)		_		_		_	275	*	21,672
Gross profit		28,066		174		306		_			-		 (275)		28,271
Gross margin %		56.2 %											` ′		56.6 %
Operating expenses:															
Sales and marketing		14,656		(682)	ı	(767)		_		_		_	_		13,207
Research and development		4,029		(34)		(325)		_		_		_	_		3,670
General and administrative		7,938		(27)	ı	(654)		_		_		(566)	_		6,691
Total operating expenses		26,623		(743)		(1,746)				_		(566)	 _		23,568
Income (loss) from operations		1,443		917		2,052		_		_		566	(275)		4,703
Interest and other income, net		7		_	0	_		_		_		_	_		7
Income (loss) before income taxes		1,450		917		2,052		_		_		566	(275)		4,710
Income tax expense		(738)		_		_		_		_		_			(738)
Net income (loss)	\$	2,188	\$	917	\$	2,052	\$	_	\$		\$	566	\$ (275)	\$	5,448
Net income (loss) per share:															
Basic	\$	0.12												\$	0.31
Weighted-average number of shares used in per share calculations:															
Basic		17,653													17,653
Operating expenses as a % of net revenue		GAAP												No	n-GAAP
Sales and marketing		29.3 %													26.4 %
Research and development		8.1 %													7.3 %
General and administrative		15.9 %													13.4 %
		53.3 %													47.1 %

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data) (unaudited)

	Twelve Months Ended December 31, 2021													
		GAAP	_	Depreciation and Amortization	Stock-Based Compensation	CRM and ERP Implementation Cost	Severance (RIF)	Legal - Lutronic	Other Adjustments	Non-GAAP				
Net revenue	\$	231,270		_	_	_	_	_	_	\$ 231,270				
Cost of revenue		98,165		(526)	(1,408)	_	_	_	791	97,022				
Gross profit		133,105	_	526	1,408	_	_	_	(791)	134,248				
Gross margin %		57.6 %	ó							58.0				
Operating expenses:														
Sales and marketing		76,762		(2,420)	(3,160)	(182)	(638)	_	_	70,362				
Research and development		21,568		(182)	(2,784)	_	_	_	_	18,602				
General and administrative		32,945		(60)	(5,820)	(1,316)	_	(1,201)	_	24,548				
Total operating expenses		131,275	131275	(2,662)	(11,764)	(1,498)	(638)	(1,201)		113,512				
Income (loss) from operations		1,830		3,188	13,172	1,498	638	1,201	(791)	20,736				
Interest and other income (expense), net														
Amortization of debt issuance costs		(710)		_	_	_	_	_	_	(710)				
Interest on convertible notes		(2,514)		_	_	_	_	_	_	(2,514)				
Gain on extinguishment of PPP loan		7,185		_	_	_	_	_	(7,185)	_				
Other expense		(2,406)		_	_	_	_	_	_	(2,406)				
Total interest and other income (expense), net		1,555	_'						(7,185)	(5,630)				
Income (loss) before income taxes		3,385		3,188	13,172	1,498	638	1,201	(7,976)	15,106				
Income tax expense		1,323		_	_	_	_	_	_	1,323				
Net income (loss)	\$	2,062	_	\$ 3,188	\$ 13,172	\$ 1,498	\$ 638	\$ 1,201	\$ (7,976)	\$ 13,783				
Net income (loss) per share:														
Basic	\$	0.12	_							\$ 0.77				
Weighted-average number of shares used in per share calculations:														
Basic		17,891	-							17,891				
Operating expenses as a % of net revenue		GAAP								Non-GAAP				
Sales and marketing		33.2 %	<u></u>							30.4				
Research and development		9.3 %								8.0				
General and administrative		14.2 9								10.6				
	_	56.7 %	_							49.0				

RECONCILIATION OF GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data) (unaudited)

Twelve Months Ended December 31, 2020

		GAAP	Deprec an Amorti	d	Stock-Ba Compensa		CRM and ER Implementatio write-off		Severance (RIF)	Legal/For Settlement		Othe Adjustn		N	on-GAAP
Net revenue	\$	147,683												¢	147,683
Cost of revenue	Ф	71,911		(591)		(1,665)	-		(318)				— 275	\$	69,612
	_	75,772		591		1,665			318				(275)		78,071
Gross profit Gross margin %		51.3 %		591		1,005	-		318		_		(2/5)		78,071 52.9 %
Gross margin %		31.3 %													32.9 %
Operating expenses:															
Sales and marketing		52,766		(3,136)		(3,384)	-	_	(274)		_		_		45,972
Research and development		14,322		(149)		(1,670)	-	_	(130)		_		_		12,373
General and administrative		31,512		(111)		(3,390)	(1,13	9)	(101)		(1,925)		(324)		24,522
Total operating expenses		98,600		(3,396)		(8,444)	(1,13	9)	(505)		(1,925)		(324)		82,867
Income (loss) from operations		(22,828)		3,987		10,109	1,13	9	823		1,925		49		(4,796)
Interest and other expense, net		(579)		_		_	-	_	_		_		_		(579)
Income (loss) before income taxes		(23,407)		3,987		10,109	1,13	9	823		1,925		49		(5,375)
Income tax expense		470		_		_		_	_		_		9		479
Net income (loss)	\$	(23,877)	\$	3,987	\$	10,109	\$ 1,13	9 \$	823	\$	1,925	\$	40	\$	(5,854)
Net income (loss) per share:															
Basic	\$	(1.43)												\$	(0.35)
Weighted-average number of shares used in per share calculations:															
Basic		16,691													16,691
Operating expenses as a % of net revenue		GAAP												N	on-GAAP
Sales and marketing		35.7 %													31.1 %
Research and development		9.7 %													8.4 %
General and administrative		21.3 %													16.6 %
		66.7 %													56.1 %

CUTERA, INC. RECONCILIATION OF LOSS TO ADJUSTED EBITDA (in thousands) (unaudited)

	Three Months Ended	Twelve Months Ended
	 December 31, 2021	
Net Income	\$ (3,935)	\$ 2,062
Adjustments:		
Stock-based compensation	4,665	13,172
Depreciation and amortization	740	3,188
ERP implementation cost	711	1,498
Severance	_	638
Legal - Lutronic	222	1,201
Other adjustments	_	(791)
Gain on extinguishment of PPP loan	_	(7,185)
Other expense	1,425	5,630
Income tax expense	481	1,323
Total adjustments	8,244	18,674
Adjusted EBITDA	\$ 4,309	\$ 20,736